ethirimol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ethirimol : An aminopyrimidine that is 2-ethylaminopyrimidin-4-one carrying butyl and methyl substituents at positions 5 and 6 respectively. A fungicide first marketed in 1970 and used as a seed treatment for diseaases such as damping-off, it is not licensed for use within the European Union. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 135424354 |
| CHEMBL ID | 1863416 |
| CHEBI ID | 81989 |
| SCHEMBL ID | 20692 |
| SCHEMBL ID | 10391126 |
| MeSH ID | M0050970 |
| Synonym |
|---|
| milstem seed dressing |
| 5-n-butyl-2-ethylamino-4-hydroxy-6-methylpyrimidine |
| nsc 263491 |
| epa pesticide chemical code 228900 |
| ethyrimol |
| ethirimol [bsi:iso] |
| 5-butyl-2-(ethylamino)-6-methyl-4-pyrimidinol |
| einecs 245-949-3 |
| 5-butyl-2-(ethylamino)-6-methyl-4(1h)-pyrimidinone |
| new milstem |
| ethyrimol [iso:french] |
| brn 0882476 |
| caswell no. 128h |
| 2-ethylamino-4-methyl-5-n-butyl-6-hydroxypyrimidine |
| pp149 |
| AKOS015843248 |
| ethrimiol |
| milgo e |
| ethirimol |
| nsc-263491 |
| pp 149 |
| 23947-60-6 |
| 4(3h)-pyrimidinone, 5-butyl-2-(ethylamino)-6-methyl- |
| milgo |
| 4(1h)-pyrimidinone, 5-butyl-2-(ethylamino)-6-methyl- |
| nsc263491 |
| milstem |
| 5-butyl-2-ethylamino-4-hydroxy-6-methylpyrimidine |
| 5-butyl-2-(ethylamino)-4-hydroxy-6-methylpyrimidine |
| ethirimal |
| 4-(1h)pyrimidinone, 5-butyl-2-(ethylamino)-6-methyl- |
| 5-butyl-2-(ethylamino)-6-methyl-1h-pyrimidin-4-one |
| dndi1255616 |
| CHEMBL1863416 |
| chebi:81989 , |
| C18828 |
| cas-23947-60-6 |
| tox21_301780 |
| NCGC00255983-01 |
| dtxsid6041927 , |
| dtxcid4021927 |
| zff86y4na6 , |
| unii-zff86y4na6 |
| FT-0630507 |
| AKOS015892467 |
| eth 560 |
| pp-149 |
| ethirimol [iso] |
| milstem (zeneca) |
| eth-560 |
| milgo (zeneca) |
| 5-butyl-2-ethylamino-6-methylpyrimidin-4-ol |
| milcurb super |
| ethirimol [mi] |
| milcurb super (zeneca) |
| SCHEMBL20692 |
| 5-butyl-2-(ethylamino)-6-methylpyrimidin-4(1h)-one |
| SCHEMBL10391126 |
| J-520458 |
| ethirimol, pestanal(r), analytical standard |
| J-015288 |
| Q3059320 |
| 5-butyl-2-(ethylamino)-6-methylpyrimidin-4-ol |
| AS-14740 |
| AMY8987 |
| D93193 |
| 5-butyl-2-(ethylamino)-4-methyl-1h-pyrimidin-6-one |
| Role | Description |
|---|---|
| antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| aminopyrimidine | A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives. |
| pyrimidone | A pyrimidine carrying one or more oxo substituents. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| pyrimidine fungicide | Any pyrimidine antifungal agent that has been used as a fungicide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 43.2771 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||